| Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) | TA972 | | |
| Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis | TA312 | | |
| Cladribine for treating relapsing–remitting multiple sclerosis | TA616 | | |
| Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis | TA127 | | |
| Ranibizumab for treating choroidal neovascularisation associated with pathological myopia | TA298 | | |
| Ranibizumab and pegaptanib for the treatment of age-related macular degeneration | TA155 | | |
| Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion | TA283 | | |
| Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes | IPG787 | | |
| Image-guided percutaneous laser ablation for primary and secondary liver tumours | IPG788 | | |
| Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver | IPG786 | | |
| Atogepant for preventing migraine | TA973 | | |
| Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma | TA974 | | |
| Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under | TA975 | | |
| Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer | DG58 | | |
| Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments | TA970 | | |
| Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 | TA971 | | |
| Artificial intelligence (AI)-derived software to help clinical decision making in stroke | DG57 | | |
| Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma | TA540 | | |
| Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over | TA967 | | |
| Digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD: early value assessment | HTE18 | | |
| Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) | TA969 | | |
| Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA968 | | |
| Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) | TA966 | | |
| Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema | IPG785 | | |
| Cabozantinib with nivolumab for untreated advanced renal cell carcinoma | TA964 | | |